Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 16/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886108 | 0.79 | KEAP1 (0.52) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3042681 | 0.78 | KEAP1 (0.51) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2454545 | 0.77 | CYP11B1 (0.46) | CHRM3CHRM2CHRM1ALDH1A1CYP1A2 | |
| SCHEMBL3041391 | 0.76 | ALDH1A1 (0.54) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3042248 | 0.75 | POLB (0.54) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3055269 | 0.74 | HTT (0.58) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3047459 | 0.74 | CHRM2 (0.49) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL16209859 | 0.73 | CHRM3 (0.78) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4883203 | 0.73 | CHRM3 (0.78) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4892749 | 0.73 | CHRM3 (0.68) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417106-B1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2016-11-30 | — | — | EP | disclosed |
| EP-2417106-B1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2016-11-30 | — | — | EP | disclosed |
| EP-2417106-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20120022127-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20120022127-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20120022127-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115937-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115937-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022127-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | C1S, C1R, C9 | KEAP1 2968/4885NFE2L2 3291/4885CHRM3 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.